Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations

Journal of Cystic Fibrosis

Volumn 6, Issue 2, 2007, Pages 125-130

  Coulthard, Kingsley P ^a   Peckham, Daniel G ^b   Conway, Steven P ^b   Smith, Carol A ^a   Bell, Jan ^a   Turnidge, John ^c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b Leeds Regional Paediatric Cystic Fibrosis Centre   (United Kingdom)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Area under curve; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CREATININE; TOBRAMYCIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; HUMAN; INTERMETHOD COMPARISON; RECOMMENDED DRUG DOSE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; PSEUDOMONAS INFECTIONS; SPUTUM; TOBRAMYCIN;

EID: 33847753552     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.05.015     Document Type: Article

References (31)

1. Master V., Roberts G.W., Coulthard K.P., et al. Efficacy of once-daily tobramycin monotherapy in acute pulmonary exacerbation of cystic fibrosis. Pediatr Pulmonol 31 (2001) 367-376
2. Whitehead A., Conway S.P., Etherington C., Caldwell N.A., Setchfield N., and Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 19 (2002) 303-309
3. Smyth A., Tan K., Hyman-Taylor P., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC STUDY: a randomised controlled trial. Lancet 365 (2005) 573-578
4. Konrad F., Wagner R., Neumeister B., Rommel H., and Georgieff M. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 19 (1993) 215-220
5. Barclay M.L., Begg E.J., Duffull S.B., and Buttimore R.C. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med 25 (1995) 230-235
6. Tod M.M., Padoin C., and Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring. Simple or complex pharmacokinetic methods?. Clin Pharmacokinet 40 (2001) 803-814
7. Barclay M.L., Kirkpatrick C.M.J., and Begg E.J. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?. Clin Pharmacokinet 36 (1999) 89-98
8. Alvarez J.S., Sacristan J.A., and Alsar M.J. Aminoglycosides: determination of new therapeutic ranges. Ann Pharmacother 25 (1991) 558 [Letter to Editor]
9. Al-Aloul M., Miller H., Alapati S., Stockton P.A., Ledson M.J., and Walshaw M.J. Renal impairment in cystic fibrosis due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 39 (2005) 15-20
10. Begg E.J., Barclay M.L., and Duffull S.B. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39 (1995) 605-609
11. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., and Craig W.A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158 (1988) 831-847
12. Tunridge J., Bell J., and Mascaro L. The peak-AUC method for aminoglycoside dosage adjustment. Program and abstracts of 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans (1996 (September)) Abstract
13. Paterson D.L., Robson J.M.B., Wagener M.M., and Peters M. Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology 30 (1998) 289-294
14. Bates R.D., Nahata M.C., Jones J.W., et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 112 (1997) 1208-1213
15. Vic P., Turck D., Husson M.O., et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 78 (1998) 536-539
16. Morris R.G., Sallustio B.C., Vinks A.A.T.M.M., LeGatt D.F., Verjee Z.H., and Desoky E.E. Some international approaches to aminoglycoside monitoring in the extended dosing interval era. Ther Drug Monit 21 (1999) 379-388
17. Wallace A.W., Jones M., and Bertino J.S. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 22 (2002) 1077-1083
18. Moore R.D., Smith C.R., and Lipsky J.D. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100 (1984) 352-357
19. Bertino J.S.J., Brooker L.A., Franck P.A., Jenkins P.L., Franck K.R., and Nafziger A.N. Incidence of the significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167 (1993) 173-179
20. Rybak M.J., Abate B.J., Kang S.L., Ruffing M.J., Lerner S.A., and Drusano G.L. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43 (1999) 1549-1555
21. Murry K.R., McKinnon P.G., Mitrzyk B., and Rybak M.J. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 19 (1999) 1252-1260
22. Mann H.J., Canafax D.M., Cipolle R.J., Daniels C.E., Zaske D.E., and Warwick W.J. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1 (1985) 238-243
23. Jameson J.P., and Lewis J.A. Three-point versus two-point method for early individualization of aminoglycoside doses. DICP Ann Pharmacother 25 (1991) 635-637
24. Lavezo L.A., and Davis R.L. Two-versus three-sample method for estimating gentamicin pharmacokinetic values. Am J Hosp Pharm 51 (1994) 1021-1024
25. Traynor A.M., Nafziger A.N., and Bertino J.S. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39 (1995) 545-548
26. Demczar D.J., Nafziger A.N., and Bertino J.S. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 41 (1997) 1115-1119
27. Aminimanizani A., Beringer P.M., King J., Tsang L., Jelliffe R.W., and Shapiro B.J. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. JAC 50 (1992) 553-559
28. Smyth A., Touw D., Tan K.H.V., Bertenshaw C., and Stableforth D. Tobramycin dosing in cystic fibrosis. Lancet 365 (2005) 1767-1768 [Letter to Editor]
29. Kirkpatrick C.M.J., and Begg E.J. Aminoglycoside dosage regimens after therapeutic drug monitoring. Clin Pharmacokinet 41 (2002) 791-792
30. Mouton J.W., Jacobs N., Tiddens H., and Horrevorts A.M. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 52 (2005) 123-127
31. Bartal C., Danon A., Schlaeffer F., et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 114 (2003) 194-198